Mécanismes de résistance et d’échappement aux cellules CAR-T

Rubio, 2018, Biologie, concepts et principes des CAR-T cells, Bull Cancer, 105, S135, 10.1016/S0007-4551(19)30044-X Larson, 2021, Recent advances and discoveries in the mechanisms and functions of CAR T cells, Nat Rev Cancer, 21, 145, 10.1038/s41568-020-00323-z Schmidts, 2021, Toward Better understanding and management of CAR-T cell–associated toxicity, Annu Rev Med, 72, 365, 10.1146/annurev-med-061119-015600 Maude, 2018, Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia, N Engl J Med, 10.1056/NEJMoa1709866 Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse Large B-cell lymphoma, N Engl J Med, 380, 45, 10.1056/NEJMoa1804980 Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial, Lancet Oncol, 20, 31, 10.1016/S1470-2045(18)30864-7 Fraietta, 2018, Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia, Nat Med, 24, 563, 10.1038/s41591-018-0010-1 Raje, 2019, Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma, N Engl J Med, 10.1056/NEJMoa1817226 Louis, 2011, Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma, Blood, 118, 6050, 10.1182/blood-2011-05-354449 Zhan, 2019, Phase I trial of Claudin 18.2-specific chimeric antigen receptor T cells for advanced gastric and pancreatic adenocarcinoma, JCO, 37, 10.1200/JCO.2019.37.15_suppl.2509 Adusumilli, 2019, Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: safety and preliminary efficacy in combination with anti-PD-1 agent, JCO, 37, 10.1200/JCO.2019.37.15_suppl.2511 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 10.1056/NEJMoa1709919 Neelapu, 2017, Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-cell lymphoma, N Engl J Med, 377, 2531, 10.1056/NEJMoa1707447 Mueller, 2017, Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia, Blood, 130, 2317, 10.1182/blood-2017-06-786129 Gardner, 2017, Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults, Blood, 129, 3322, 10.1182/blood-2017-02-769208 Gattinoni, 2012, Paths to stemness: building the ultimate antitumour T cell, Nat Rev Cancer, 12, 671, 10.1038/nrc3322 Klebanoff, 2005, Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells, PNAS, 102, 9571, 10.1073/pnas.0503726102 Calderon, 2020, Analysis of CAR-Mediated Tonic Signaling, 223 Sommermeyer, 2016, Chimeric antigen receptor-modified T cells derived from defined CD8+and CD4+subsets confer superior antitumor reactivity in vivo, Leukemia, 30, 492, 10.1038/leu.2015.247 Finney, 2019, CD19 CAR T cell product and disease attributes predict leukemia remission durability, J Clin Invest, 129, 2123, 10.1172/JCI125423 Das, 2019, Naïve T-cell deficits at diagnosis and after chemotherapy impair cell therapy potential in pediatric cancers, Cancer Discov, 9, 492, 10.1158/2159-8290.CD-18-1314 Fraietta, 2016, Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia, Blood, 127, 1117, 10.1182/blood-2015-11-679134 Jafarzadeh, 2020, Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in adoptive cancer immunotherapy: challenges and ways forward, Front Immunol, 11 Kaartinen, 2017, Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion, Cytotherapy, 19, 689, 10.1016/j.jcyt.2017.03.067 Xu, 2014, Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15, Blood, 123, 3750, 10.1182/blood-2014-01-552174 Klebanoff, 2017, Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy, JCI Insight, 2 Kochenderfer, 2017, Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 Levels, JCO, 35, 1803, 10.1200/JCO.2016.71.3024 van der Stegen, 2015, The pharmacology of second-generation chimeric antigen receptors, Nat Rev Drug Discov, 14, 499, 10.1038/nrd4597 Guedan, 2014, ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells, Blood, 124, 1070, 10.1182/blood-2013-10-535245 Maher, 2002, Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor, Nat Biotechnol, 20, 70, 10.1038/nbt0102-70 Zhao, 2015, Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells, Cancer Cell, 28, 415, 10.1016/j.ccell.2015.09.004 Zhylko, 2020, The great war of today: modifications of CAR-T cells to effectively combat malignancies, Cancers, 12, 2030, 10.3390/cancers12082030 Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838 Salter, 2018, Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function, Sci Signal, 11 Kawalekar, 2016, Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells, Immunity, 44, 380, 10.1016/j.immuni.2016.01.021 Guo, 2019, Chapter Four - Immunometabolism: a new target for improving cancer immunotherapy, 143, 195 Oluwole, 2020, Comparing efficacy, safety, and preinfusion period of axicabtagene ciloleucel versus tisagenlecleucel in relapsed/refractory large B cell lymphoma, Biol Blood Marrow Transplant, 26, 1581, 10.1016/j.bbmt.2020.06.008 Guedan, 2020, Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability, J Clin Invest, 130, 3087, 10.1172/JCI133215 Fraietta, 2018, Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells, Nature, 558, 307, 10.1038/s41586-018-0178-z Nobles, 2020, CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration, J Clin Invest, 130, 673, 10.1172/JCI130144 Sheih, 2020, Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy, Nat Commun, 11, 219, 10.1038/s41467-019-13880-1 Bai, 2015, Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA, Cell Discov, 1, 1, 10.1038/celldisc.2015.40 Rossi, 2018, Preinfusion polyfunctional anti-CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL, Blood, 132, 804, 10.1182/blood-2018-01-828343 Deng, 2020, Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas, Nat Med, 26, 1878, 10.1038/s41591-020-1061-7 Maude, 2016, Sustained remissions with CD19-specific chimeric antigen receptor (CAR)-modified T cells in children with relapsed/refractory ALL, JCO, 34 Dai, 2020, Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia, J Hematol Oncol, 13, 30, 10.1186/s13045-020-00856-8 Orlando, 2018, Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia, Nat Med, 24, 1504, 10.1038/s41591-018-0146-z Sotillo, 2015, Convergence of acquired mutations and alternative Splicing of CD19 enables resistance to CART-19 immunotherapy, Cancer Discov, 5, 1282, 10.1158/2159-8290.CD-15-1020 Maude, 2018, Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia, N Engl J Med, 378, 439, 10.1056/NEJMoa1709866 Park, 2018, Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia, N Engl J Med, 378, 449, 10.1056/NEJMoa1709919 Fry, 2018, CD22-CAR T cells induce remissions in CD19-CAR naïve and resistant B-ALL, Nat Med, 24, 20, 10.1038/nm.4441 Gardner, 2016, Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy, Blood, 127, 2406, 10.1182/blood-2015-08-665547 Jacoby, 2015, Lineage switch as a relapse mechanism of Pre-B acute lymphoblastic leukemia following CD19 CAR, Blood, 126, 10.1182/blood.V126.23.2524.2524 Ruella, 2018, Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell, Nat Med, 24, 1499, 10.1038/s41591-018-0201-9 Vercellino, 2020, Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma, Blood Adv, 4, 5607, 10.1182/bloodadvances.2020003001 Rodriguez-Garcia, 2020, CAR-T cells hit the tumor microenvironment: strategies to overcome tumor escape, Front Immunol, 11 Cheng, 2019, Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies, Front Oncol, 9 Autio, 2021, Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma, 106, 718 Pastorczak, 2021, Mechanisms of immune evasion in acute lymphoblastic leukemia, Cancers, 13, 1536, 10.3390/cancers13071536 Schuster, 2017, Chimeric antigen receptor T cells in refractory B-cell lymphomas, N Engl J Med, 377, 2545, 10.1056/NEJMoa1708566 Yan, 2019, Clinical efficacy and tumor microenvironment influence in a dose-escalation study of Anti-CD19 chimeric antigen receptor T cells in refractory B-Cell Non-Hodgkin's lymphoma, Clin Cancer Res, 25, 6995, 10.1158/1078-0432.CCR-19-0101 Jain, 2021, Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma, Blood, 137, 2621, 10.1182/blood.2020007445 Chen, 2020, Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy, JCI Insight, 5 Jensen, 2010, Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans, Biol Blood Marrow Transplant, 16, 1245, 10.1016/j.bbmt.2010.03.014 Lamers, 2011, Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells, Blood, 117, 72, 10.1182/blood-2010-07-294520 Blanco, 1997, Antiidiotypic response against murine monoclonal antibodies reactive with tumor-associated antigen TAG-72, J Clin Immunol, 17, 96, 10.1023/A:1027396714623 Kershaw, 2006, A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer, Clin Cancer Res, 12, 6106, 10.1158/1078-0432.CCR-06-1183 Awasthi, 2020, Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL, Blood Adv, 4, 560, 10.1182/bloodadvances.2019000525 European Medicines Agency. EMA - Yescarta/axicabtagene ciloleucel - Assessment report. n.d. Mueller, 2018, Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia, Clin Cancer Res, 24, 6175, 10.1158/1078-0432.CCR-18-0758 Ghorashian, 2019, Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR, Nat Med, 25, 1408, 10.1038/s41591-019-0549-5 Till, 2012, CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results, Blood, 119, 3940, 10.1182/blood-2011-10-387969 Turtle, 2016, Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor–modified T cells, Sci Transl Med, 8, 10.1126/scitranslmed.aaf8621 Brudno, 2020, Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma, Nat Med, 26, 270, 10.1038/s41591-019-0737-3 Turtle, 2016, CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients, J Clin Invest, 126, 2123, 10.1172/JCI85309 Maus, 2013, T Cells expressing chimeric antigen receptors can cause anaphylaxis in humans, Cancer Immunol Res, 1, 26, 10.1158/2326-6066.CIR-13-0006 Morgan, 2010, Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2, Mol Ther, 18, 843, 10.1038/mt.2010.24 Ahmed, 2015, Human Epidermal Growth Factor Receptor 2 (HER2)–specific chimeric antigen receptor–modified T cells for the immunotherapy of HER2-positive sarcoma, JCO, 33, 1688, 10.1200/JCO.2014.58.0225 O’Rourke, 2017, A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma, Sci Transl Med, 9 Grada, 2013, TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy, Mol Ther Nucleic Acids, 2 Kailayangiri, 2019, EZH2 inhibition in ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells, Mol Ther, 27, 933, 10.1016/j.ymthe.2019.02.014 Straathof, 2020, Antitumor activity without on-target off-tumor toxicity of GD2–chimeric antigen receptor T cells in patients with neuroblastoma, Sci Transl Med, 12 Shrimali, 2010, Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer, Cancer Res, 70, 6171, 10.1158/0008-5472.CAN-10-0153 Harlin, 2009, Chemokine expression in melanoma metastases associated with CD8+ T-Cell recruitment, Cancer Res, 69, 3077, 10.1158/0008-5472.CAN-08-2281 Nishio, 2014, Armed oncolytic virus enhances immune functions of chimeric antigen receptor–modified T cells in solid tumors, Cancer Res, 74, 5195, 10.1158/0008-5472.CAN-14-0697 Hege, 2017, Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer, J Immunother Cancer, 5, 22, 10.1186/s40425-017-0222-9 Caruana, 2015, Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes, Nat Med, 21, 524, 10.1038/nm.3833 Heiden, 2009, Understanding the Warburg Effect: the metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 Gajewski, 2006, Immune resistance orchestrated by the tumor microenvironment, Immunol Rev, 213, 131, 10.1111/j.1600-065X.2006.00442.x Jarnicki, 2006, Suppression of antitumor immunity by IL-10 and TGF-β-producing T Cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ Regulatory T Cells, J Immunol, 177, 896, 10.4049/jimmunol.177.2.896 Shah, 2019, Multi targeted CAR-T cell therapies for B-cell malignancies, Front Oncol, 9 Wang, 2019, Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies, J Hematol Oncol, 12, 59, 10.1186/s13045-019-0746-1 Liu, 2020, Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors, N Engl J Med, 382, 545, 10.1056/NEJMoa1910607 Rotolo, 2018, Enhanced anti-lymphoma activity of CAR19-iNKT cells underpinned by dual CD19 and CD1d targeting, Cancer Cell, 34, 10.1016/j.ccell.2018.08.017